Abstract
Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare 8-week glecaprevir/pibrentasvir treatment in a case-control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co-infections. About 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0 ± 9.6 years and 42.8 ± 9.9 in Group A and B, respectively (P = .74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (P = .21). Five drop-outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated with SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short-term therapies. Short schedules with pangenotypic regimens could be a good approach to hard-to-reach populations, such as incarcerated patients.
Original language | English |
---|---|
Pages (from-to) | 271-275 |
Number of pages | 5 |
Journal | Liver international : official journal of the International Association for the Study of the Liver |
Volume | 41 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 1 2021 |
Keywords
- case-control study
- direct acting antivirals
- Hepatitis C virus
- incarcerated patients
- prison settings
ASJC Scopus subject areas
- Hepatology